Actively Recruiting

Phase 4
Age: 18Years - 65Years
FEMALE
ID06690307

The Efficacy and Safety of Oxycodone in Patient-controlled Intravenous Analgesia After Laparoscopic Hysterectomy

Led by Affiliated Hospital of Nantong University · Updated on 2024-12-04

64

Participants Needed

1

Research Sites

30 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the safety and effectiveness of oxycodone compared to sulfentanil in patient-controlled intravenous analgesia (PCIA) for managing pain after gynecological laparoscopic hysterectomy. This Phase 4 study aims to find the best PCIA approach to improve postoperative pain control for patients undergoing these surgeries. Participants will be randomly assigned to one of two groups: one group will receive sulfentanil through PCIA, while the other group will receive oxycodone through PCIA. Pain levels will be measured using Numeric Rating Scale (NRS) scores at 1, 6, 24, and 48 hours after surgery. The study will also monitor the use of additional pain relief medications and any adverse events. During the trial, participants will have their pain assessed regularly and will be observed for any side effects or complications within 48 hours post-surgery. Other measures include the number of times the PCIA device is pressed, time to first anal exhaust, and pain scores up to 30 days after surgery. The total participation period includes these assessments to ensure comprehensive monitoring of pain management and safety.

CONDITIONS

Brief Title

Oxycodone Versus Sufentanil in Patient-controlled Intravenous Analgesia After Laparoscopic Hysterectomy

Who Can Participate

Age: 18Years - 65Years
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Selective laparoscopic hysterectomy
  • General anesthesia
  • ASA classification I to III
  • Female aged 18 to 65 years
Not Eligible

You will not qualify if you...

  • Allergy to oxycodone or any other drugs used in the study
  • Preoperative opioid medication
  • History of opioid abuse
  • Hepatic or renal dysfunction
  • Cardiovascular or pulmonary dysfunction
  • Lack of full civil capacity or refusal to participate

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - Up to 48 hours after surgery

Participants receive patient-controlled intravenous analgesia (PCIA) with either oxycodone or sulfentanil after laparoscopic hysterectomy.

1 hospital stay including continuous monitoring up to 48 hours post-surgery

Follow-up

Duration - 30 days after surgery

Participants are assessed for pain scores and adverse events up to 30 days after surgery.

1 follow-up visit

Trial Site Locations

Total: 1 location

1

Affiliated hospital of Nantong University

Nantong, Jiangsu, China, 226001

Actively Recruiting

Loading map...

Research Team

S

Siyuan Liu, PhD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

Effect of the Trendelenburg Position on Patient State Index ...

Laparoscopic Hysterectomy

Actively Recruiting

1 location

Comparison of Endoscopic Tissue Cutting and Abdominal Extrac...

Laparoscopic Hysterectomy

Actively Recruiting

1 location

Evaluation and Comparison Between General Anesthesia and Two...

Laparoscopic Hysterectomy

Actively Recruiting

2 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here